T Izumo, M Tone, N Kuse, N Awano… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Benralizumab is a humanized, fucosylated, monoclonal antibody that targets
the interleukin 5 (IL-5) α receptor. Several phase III trials have shown that benralizumab can …